Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, has announced the appointment of Philip Vickers, Ph.D., to its Board of Directors, effective April 1, 2026. Dr. Vickers brings over three decades of experience in the biopharmaceutical industry, having held leadership roles in various biotechnology and pharmaceutical companies. His expertise spans research and development, translational science, and corporate strategy across multiple therapeutic areas.

The appointment comes at a pivotal time for Akebia as it seeks to advance its mid- and early-stage programs targeting kidney and rare diseases. Adrian Adams, Chairperson of the Board, expressed enthusiasm about Dr. Vickers joining the team, highlighting his extensive background in drug development and his proven track record in evaluating business development opportunities. Dr. Vickers' experience is expected to be invaluable as Akebia navigates its strategic initiatives.

In conjunction with this appointment, Akebia also announced the resignation of Steven C. Gilman, Ph.D., a Class I director, effective April 1, 2026. Dr. Gilman has been a member of the Board since the merger with Keryx in December 2018 and has played a significant role in the company's development and commercialization efforts, particularly with the approval of Vafseo® (vadadustat).

Dr. Vickers will receive compensation in line with Akebia's Fifth Amended and Restated Non-Employee Director Compensation Program, which includes an annual cash retainer and equity grants. His initial term is set to expire at the company’s 2027 annual meeting of stockholders. This leadership change is expected to positively influence Akebia's strategic direction and operational execution as it continues to focus on its mission to better the lives of patients with kidney disease.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.